Skip to main content
Erschienen in: Endocrine 3/2016

15.06.2016 | Original Article

Do patients with incidentally discovered bilateral adrenal nodules represent an early form of ARMC5-mediated bilateral macronodular hyperplasia?

verfasst von: Holly Emms, Ioanna Tsirou, Treena Cranston, Stylianos Tsagarakis, Ashley B. Grossman

Erschienen in: Endocrine | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Bilateral adrenal macronodular hyperplasia (BMAH) is a rare form of Cushing’s syndrome characterised by the presence of bilateral secretory adrenal nodules and hypercortisolism. Familial studies support a genetic basis for BMAH, and the disease has been linked to mutations in ARMC5, a gene shown to have a tumour suppressor-like action in the development of adrenal nodules. This study aimed to investigate whether ARMC5 mutations play a role in the development of incidentally discovered bilateral adrenal nodules. We investigated 39 patients with incidentally discovered bilateral adrenal nodules >0.8 cm in diameter who underwent extensive biochemical testing to look for signs of subclinical hypercortisolism. Genomic DNA was analysed by Sanger sequencing, using primers targeted to ARMC5 transcripts. Of the 39 patients included in our study, three were identified as having variants in ARMC5. Two of these are unlikely to be clinically significant, but there is evidence that the third mutation, Chr16:g.31476122;c.1778G>C (p.Arg593Pro), may be pathogenic. Another variant, affecting the same amino-acid residue c.1777C>T (p.Arg593Trp), has been identified previously in two studies of BMAH patients, where it has been shown to segregate with disease in one BMAH family. This patient had biochemical evidence of hypercortisolism in the absence of overt Cushing’s syndrome, and underwent bilateral adrenalectomy separated in time. The presence of a probably clinically significant mutation in ARMC5 in one patient with bilateral adrenal incidentalomas adds to the growing body of evidence in support of ARMC5 as a critical mediator of adrenal nodule development. In addition, the absence of significant ARMC5 mutations in 38 of our patients represents an important negative finding, demonstrating the degree of variability within the pathogenesis of adrenal nodule development.
Literatur
1.
Zurück zum Zitat A. Lacroix, ACTH-independent macronodular adrenal hyperplasia. Best Pract Res: Clin Endocrinol Metab 23, 245–259 (2009)CrossRef A. Lacroix, ACTH-independent macronodular adrenal hyperplasia. Best Pract Res: Clin Endocrinol Metab 23, 245–259 (2009)CrossRef
2.
Zurück zum Zitat E. Louiset, C. Duparc, J. Young et al., Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 369, 2115–2125 (2013)CrossRefPubMed E. Louiset, C. Duparc, J. Young et al., Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N. Engl. J. Med. 369, 2115–2125 (2013)CrossRefPubMed
3.
Zurück zum Zitat J.M. Swain, C.S. Grant, R.T. Schlinkert et al., Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathologic correlation. Arch. Surg. 133, 541–546 (1998)CrossRefPubMed J.M. Swain, C.S. Grant, R.T. Schlinkert et al., Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathologic correlation. Arch. Surg. 133, 541–546 (1998)CrossRefPubMed
4.
Zurück zum Zitat G. Assié, R. Libé, S. Espiard et al., ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N. Engl. J. Med. 369, 2105–2114 (2013)CrossRefPubMedPubMedCentral G. Assié, R. Libé, S. Espiard et al., ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N. Engl. J. Med. 369, 2105–2114 (2013)CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat F.R. Faucz, M. Zilbermint, M.B. Lodish et al., Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J. Clin. Endocrinol. Metab. 99, E1113–E1119 (2014)CrossRefPubMedPubMedCentral F.R. Faucz, M. Zilbermint, M.B. Lodish et al., Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J. Clin. Endocrinol. Metab. 99, E1113–E1119 (2014)CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat L. Gagliardi, A.W. Schreiber, C.N. Hahn et al., ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 99, E1784–E1792 (2014)CrossRefPubMed L. Gagliardi, A.W. Schreiber, C.N. Hahn et al., ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 99, E1784–E1792 (2014)CrossRefPubMed
7.
Zurück zum Zitat R.T. Kloos, M.D. Gross, I.R. Francis, M. Korobkin, B. Shapiro, Incidentally discovered adrenal masses. Endocr. Rev. 16, 460–484 (1995)PubMed R.T. Kloos, M.D. Gross, I.R. Francis, M. Korobkin, B. Shapiro, Incidentally discovered adrenal masses. Endocr. Rev. 16, 460–484 (1995)PubMed
8.
Zurück zum Zitat D.A. Vassiliadi, G. Ntali, E. Vicha, S. Tsagarakis, High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin. Endocrinol. 74, 438–444 (2011)CrossRef D.A. Vassiliadi, G. Ntali, E. Vicha, S. Tsagarakis, High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin. Endocrinol. 74, 438–444 (2011)CrossRef
9.
Zurück zum Zitat R. Rossi, L. Tauchmanova, A. Luciano et al., Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85, 1440–1448 (2000)PubMed R. Rossi, L. Tauchmanova, A. Luciano et al., Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85, 1440–1448 (2000)PubMed
13.
Zurück zum Zitat P. Mulatero, F. Schiavi, T.A. Williams et al., ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. J. Hum. Hypertens. 30, 374–378 (2015)CrossRefPubMed P. Mulatero, F. Schiavi, T.A. Williams et al., ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. J. Hum. Hypertens. 30, 374–378 (2015)CrossRefPubMed
14.
15.
Zurück zum Zitat A. Lacroix, N. N’Diaye, J. Tremblay, P. Hamet, Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr. Rev. 22, 75–110 (2001)PubMed A. Lacroix, N. N’Diaye, J. Tremblay, P. Hamet, Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr. Rev. 22, 75–110 (2001)PubMed
16.
Zurück zum Zitat I. Bourdeau, P. D’Amour, P. Hamet, J.M. Boutin, A. Lacroix, Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing’s syndrome. J. Clin. Endocrinol. Metab. 86, 5534–5540 (2001)PubMed I. Bourdeau, P. D’Amour, P. Hamet, J.M. Boutin, A. Lacroix, Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing’s syndrome. J. Clin. Endocrinol. Metab. 86, 5534–5540 (2001)PubMed
17.
Zurück zum Zitat N. Miyamura, T. Taguchi, Y. Murata et al., Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine 19, 319–325 (2002)CrossRefPubMed N. Miyamura, T. Taguchi, Y. Murata et al., Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine 19, 319–325 (2002)CrossRefPubMed
18.
Zurück zum Zitat D. Vezzosi, D. Carter, C. Régnier et al., Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur. J. Endocrinol. 156, 21–31 (2007)CrossRefPubMed D. Vezzosi, D. Carter, C. Régnier et al., Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur. J. Endocrinol. 156, 21–31 (2007)CrossRefPubMed
19.
Zurück zum Zitat D.A. Vassiliadi, M. Tzanela, V. Tsatlidis et al., Abnormal responsiveness to dexamethasone-suppressed CRH test in patients with bilateral adrenal incidentalomas. J. Clin. Endocrinol. Metab. 100, 3478–3485 (2015)CrossRefPubMed D.A. Vassiliadi, M. Tzanela, V. Tsatlidis et al., Abnormal responsiveness to dexamethasone-suppressed CRH test in patients with bilateral adrenal incidentalomas. J. Clin. Endocrinol. Metab. 100, 3478–3485 (2015)CrossRefPubMed
20.
Zurück zum Zitat C.A. Stratakis, S.A. Boikos, Genetics of adrenal tumors associated with Cushing’s syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat. Clin. Pract. Endocrinol. Metab. 3, 748–757 (2007)CrossRefPubMed C.A. Stratakis, S.A. Boikos, Genetics of adrenal tumors associated with Cushing’s syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat. Clin. Pract. Endocrinol. Metab. 3, 748–757 (2007)CrossRefPubMed
Metadaten
Titel
Do patients with incidentally discovered bilateral adrenal nodules represent an early form of ARMC5-mediated bilateral macronodular hyperplasia?
verfasst von
Holly Emms
Ioanna Tsirou
Treena Cranston
Stylianos Tsagarakis
Ashley B. Grossman
Publikationsdatum
15.06.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0988-4

Weitere Artikel der Ausgabe 3/2016

Endocrine 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.